Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 6, 1998, Pages 646-654

  Jorga, Karin M ^a   Kroodsma, Jan Martin ^a   Fotteler, Baerbel ^a   Heizmann, Peter ^a   Meyer, Joseph ^a   Rasch, Mareike C ^a   Van Hattum, Jan ^a  

^a F Hoffmann La Roche ^*

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; TOLCAPONE;

ADULT; ARTICLE; CARBOXYLATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER METABOLISM; METHYLATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ULTRAVIOLET SPECTROPHOTOMETRY;

ADULT; ANTIPARKINSON AGENTS; BENZOPHENONES; CROSS-OVER STUDIES; ENZYME INHIBITORS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER DISEASES; MALE; MIDDLE AGED; NITROPHENOLS;

EID: 0031819188     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90088-1     Document Type: Article

References (20)

1. Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50:47-55.
2. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zurcher G, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-17.
3. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62.
4. Jorga K, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken J. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther 1997;62:300-10.
5. Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment - the Tolcapone Stable Study Group. Neurology 1997; 49:665-71.
6. Baas H, Beiske A, Ghika J, Jackson M, Oertel WH, Poewe W, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63:421-8.
7. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: clinical pharmacokinetics in special populations. Clin Pharmacokinet 1995;29:370-91.
8. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease: clinical pharmacokinetics and disease processes. Clin Pharmacokinet 1991;21:42-69.
9. Breimer D. Pharmacokinetics in liver disease. Pharm Weekbl [Sci] 1987;9:79-84.
10. Hayes PC. Liver disease and drug disposition. Br J Anaesth 1992;68:459-61.
11. Secor JW, Schenker S. Drug metabolism in patients with liver disease. Adv Intern Med 1987;32:379-406.
12. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology 1991; 13:786-95.
13. Child C, Turcotte J. The liver and portal hypertension. Philadelphia: WB Saunders; 1965.
14. Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989;24:269-76.
15. Orrego H, Israel Y, Blake J, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1993;3:896-905.
16. Trey C, Burns D, Saunders S. Treatment of hepatic coma by exchange blood transfusion. N Engl J Med 1966; 274:473-81.
17. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
18. Tozer TN. Implications of altered plasma protein binding in disease states. In: Benet LZ, editor. Pharmacokinet Basis Drug Treatment. New York: Raven Press; 1984. p. 173-93.
19. Øie S, Tozer T. Effect of altered plasma protein binding. J Pharm Sci 1979;68:1202-5.
20. Rowland M, Benet LZ, Graham G. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1973; 1:123-36.